ABVC News and Press, ABVC BioPharma Inc. From 03/31/22

Fremont, CA - ( NewMediaWire ) - March 31, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy with low toxicity for improved health outcomes, today announced its financial and operating results for...

Adagio Therapeutics (ADGI) +64% as COVID drug ADG20 meets main goals in trial; EUA filing in Q2. Vyant Bio (VYNT) +29% on FY results. Sonoma Pharmaceuticals (SNOA) +24% launches new urinary tract infection product through distributors in New Zealand, Australia and Sou...

Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating...

ABVC Biopharma (NASDAQ:ABVC) is trading ~7% higher in the pre-market after announcing the Principal Investigator Meeting related to its Phase II Part 2 trial for its ADHD candidate ABV-1505 will take place on Feb. 14, 2022. The lead investigators of the study from the University of California...

Fremont, CA - ( NewMediaWire ) - February 02, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase...

Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA - ( NewMediaWire ) - January 05, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, t...

Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolo...

Fremont, CA - ( NewMediaWire ) - December 22, 2021 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, the world's first bio-degradable vitreous...

Fremont, CA - ( NewMediaWire ) - December 15, 2021 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, its vitreous substitute intended to facil...

Shares of ABVC Biopharma (ABVC +11.8%) are higher after the company yesterday announced a dietary supplement distribution deal and an analyst today wrote a favorable report. ABVC's BioKey subsidiary is in a a three-year distribution deal with Taiwan-based Define Biotech. Zacks Small Cap Resea...